Two drug developers with keenly awaited late-stage trial programs have confirmed they are on schedule for crucial read-outs in early to mid 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback